Patent SG-11201909290T-A (SG)
Title: Assay to measure the potency of receptor-ligand interactions in nanomedicines
Inventor: SANTAMARIA PEDRO
IPC: C07K14/725
Filed: 2018-04-05
Abstract: P 0.0095 2 - I 0 10 20 30 40 50 Valency (number of pMHC per NP) w . 4 , _ - r 0009 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo HE (10) International Publication Number WO 2018/185564 A3 (51) International Patent Classification: Cl 2N 5/10 (2006.01) Cl 2N 15/85 (2006.01) C07K 14/725 (2006.01) C12Q 1/02 (2006.01) (21) International Application Number: PCT/IB2018/000510 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,298 07 April 2017 (07.04.2017) US (71) Applicant: UTI LIMITED PARTNERSHIP [CA/CA]; 3553 31st Street NW, Suite 130, Calgary, AB T2L 2K7 (CA). (72) Inventor: SANTAMARIA, Pedro; 6923 Christie Estates Blvd. SW, Calgary, AB T3H 2S3 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: ASSAY TO MEASURE THE POTENCY OF RECEPTOR-LIGAND INTERACTIONS IN NANOMEDICINES pMFIC density (number of pIVIHC per 100 nm 2 surface area) 0.0 01 OA 0.6 0.8 1.0 6 pMHC density (nu ber f pMHC per 100 m 2 surface area) -0,0 0,2 OA 0,6 0.8 1,0 I I I 4 c 3 4 3_ LLB. 1 I I I I 0 10 20 30 40 50 Valency (number of OA HC per NP) cc 00 FIG. 1H (57) : Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR- pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease- relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer. [Continued on next page] WO 2018/185564 A3 MIDEDIMO1101DEIRDE101011101111111111111111111111M111110fin# (88) Date of publication of the international search report: 03 January 2019 (03.01.2019)